Medplus Health Services
Market cap ₹7,193 Cr
- P/E
- 34.07
- Day range
- ₹595.30 – ₹608.85
- 52-week range
- ₹565.60 – ₹1,022.20
- Volume
- 1.51 L
- Open
- ₹608.85
- Prev close
- ₹608.85
Latest results · Q2 FY27(consolidated)Revenue ₹2,037 Cr+21.3%Profit ₹56 Cr+1.0%Margin 2.8%YoY vs the same quarter last year
1 red flag to read up on
- high
Promoter pledge went up
74.09% of promoter shares pledged, up from 60.74% · 30 Sept 2026
From NSE and BSE filings. A flag is a reason to read the filing, not a rating.
MEDPLUS in NSE indices and F&O
Research profile
Composite 44 / 100Factor percentiles
Derived metrics
- Earn. yield
- 2.9%
- Graham no.
- ₹256.92
- vs Graham
- -57.2%
- ROE ÷ P/B
- 3.3%
- 12-1 mom.
- -20.0%
- Return / vol
- -0.73
- Magic Formula
- #423
- FCF yield
- 5.2%
Appears in 8 scans
Percentiles rank this stock against the other tracked stocks and change as they do. Scans describe where figures sit today. Hover a label for its definition. Not investment advice.
Peer comparison
All 90 in Consumer| Company | M-cap | P/E | P/B | ROE | ROCE | OPM | D/E | Sales YoY |
|---|---|---|---|---|---|---|---|---|
| Titan CompanyTITAN | ₹4.12 L Cr | 58.67 | 23.83 | 37.1% | 21.0% | 14.0% | 1.51 | +10.1% |
| Asian PaintsASIANPAINT | ₹2.47 L Cr | 51.14 | 11.23 | 21.6% | 26.0% | 16.0% | 0.21 | +16.9% |
| Avenue SupermartsDMART | ₹2.26 L Cr | 72.59 | 8.60 | 12.9% | 17.0% | 7.0% | 0.16 | +17.8% |
| TrentTRENT | ₹1.70 L Cr | 89.73 | 21.75 | 27.7% | 28.0% | 18.0% | 0.30 | +21.9% |
| Lenskart SolutionsLENSKART | ₹1.27 L Cr | 162.33 | 13.71 | 6.8% | 8.0% | 22.0% | 0.37 | +35.7% |
| The Indian Hotels CompanyINDHOTEL | ₹1.25 L Cr | 56.35 | 9.29 | 18.6% | 17.0% | 28.0% | 0.25 | +21.7% |
| MeeshoMEESHO | ₹1.17 L Cr | 188.64 | 27.61 | -46.6% | -40.0% | -6.0% | 0.01 | +34.4% |
| Medplus Health ServicesMEDPLUS | ₹7,193 Cr | 34.07 | 3.60 | 11.8% | 13.0% | 8.0% | 0.75 | +21.3% |
| Sector median | ₹10,665 Cr | 40.83 | 4.83 | 13.0% | 15.0% | 12.5% | 0.27 | +19.1% |
Sector as classified in the tracked universe; medians use every tracked Consumer company, and P/E only profitable ones. Tinted figures beat the median.
Latest news
Updated 11h agoHeadlines about Medplus Health Services from the last two weeks in the financial press. Stories belong to their publishers; Rajat Finance does not endorse them.
Key metrics
- P/E (TTM)
- 35.2
- Price / Book
- 3.49
- ROE (FY26)
- 11.8%
- ROCE (latest year)
- 13%
- Dividend yield
- 0.00%
Moving averages (NSE)
- 20-day
- ₹604.28
- Price below
- 50-day
- ₹629.71
- Price below
- 200-day
- ₹769.9
- Price below
Charts & trends
From company filings. Amounts in ₹ crore.
Revenue, profit & margin - quarterly
₹ crore; a loss shows red. Operating margin below, same periods.
- Revenue
- Net profit
Operating margin
Who owns the company
% of equity by quarter, latest Sept 2026
- Promoter
- DII
- Public
- FII
- Others
Cash flows
Where cash came from and went, by fiscal year (₹ crore)
- Operating
- Investing
- Financing
- Free cash flow
Return on equity
Net profit over shareholders' equity, by fiscal year
Equity vs debt
Shareholders' equity against borrowings (₹ crore); the ratio below, same years.
- Equity
- Debt
Debt to equity
Financial statements
| Line item | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,441 | 1,490 | 1,489 | 1,576 | 1,561 | 1,510 | 1,543 | 1,679 | 1,806 | 1,864 | 1,880 | 2,037 |
| Expenses | 1,350 | 1,385 | 1,395 | 1,452 | 1,429 | 1,373 | 1,412 | 1,530 | 1,648 | 1,695 | 1,746 | 1,867 |
| Operating Profit | 92 | 106 | 94 | 124 | 133 | 136 | 131 | 149 | 159 | 169 | 133 | 170 |
| OPM % | 6% | 7% | 6% | 8% | 8% | 9% | 8% | 9% | 9% | 9% | 7% | 8% |
| Other Income | 10 | 10 | 9 | 12 | 13 | 16 | 15 | 17 | 18 | 21 | 20 | 21 |
| Interest | 24 | 25 | 25 | 25 | 26 | 27 | 27 | 29 | 31 | 33 | 33 | 37 |
| Depreciation | 57 | 59 | 60 | 63 | 62 | 64 | 66 | 69 | 73 | 76 | 78 | 84 |
| Profit before tax | 20 | 32 | 18 | 48 | 57 | 61 | 53 | 69 | 73 | 80 | 42 | 70 |
| Tax % | 31% | -5% | 19% | 19% | 19% | 16% | 20% | 19% | 21% | 20% | 21% | 20% |
| Net Profit | 14 | 34 | 14 | 39 | 46 | 51 | 42 | 56 | 58 | 64 | 33 | 56 |
| EPS in Rs | ₹1.15 | ₹2.79 | ₹1.20 | ₹3.24 | ₹3.83 | ₹4.29 | ₹3.54 | ₹4.63 | ₹4.82 | ₹5.33 | ₹2.76 | ₹4.67 |
From company filings, updated 17 Nov 2026. Consolidated figures where the company reports them. Information only, not investment advice.
Working-capital cycle
0 days since Mar 2021
-14 days since Mar 2021
0 days since Mar 2021
-12 days since Mar 2021
+3 days since Mar 2021
Strengths, risks & growth
Strengths
- Company has delivered good profit growth of 28.4% CAGR over last 5 years
Risks
- Stock is trading at 3.59 times its book value
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has a low return on equity of 8.38% over last 3 years.
- Promoters have pledged 74.1% of their holding.
Compounded Sales Growth
- 10 Years
- +15%
- 5 Years
- +18%
- 3 Years
- +15%
- TTM
- +21%
Compounded Profit Growth
- 10 Years
- +37%
- 5 Years
- +28%
- 3 Years
- +66%
- TTM
- +8%
Stock Price CAGR
- 10 Years
- —
- 5 Years
- —
- 3 Years
- -9%
- 1 Year
- -21%
Return on Equity
- 10 Years
- +8%
- 5 Years
- +7%
- 3 Years
- +8%
- Last Year
- +12%
Strengths and risks are a machine-generated checklist, not advice; growth is compounded annually over each period.
Shareholding pattern
| Holder | Dec 2025 | Mar 2026 | Jun 2026 | Sept 2026 | Change |
|---|---|---|---|---|---|
| Promoter | 40.29% | 40.22% | 40.19% | 40.20% | +0.01 pp |
| FII | 16.83% | 15.53% | 14.38% | 12.58% | -1.80 pp |
| DII | 26.58% | 27.82% | 29.95% | 31.89% | +1.94 pp |
| Public | 16.27% | 16.41% | 15.45% | 15.31% | -0.14 pp |
| Others | 0.04% | 0.04% | 0.04% | 0.04% | 0.00 pp |
Filed with NSE for Sept 2026: promoters 40.19%, public 59.76%
Analysts & fund holdings
Who holds the shares, quarter by quarter
Mutual funds 27.40% (+2.88 pp)- Promoters40.2%
- Foreign institutions12.6%
- Mutual funds27.4%
- Insurance1.2%
- Other domestic institutions3.3%
- Retail9.0%
- Others6.3%
| Fund | % of company | % of fund | 3-month change |
|---|---|---|---|
| ICICI Pru Healthcare Fund | 4.11% | 4.30% | +0.50 pp |
| Kotak Small Cap Fund | 2.99% | 1.16% | -0.17 pp |
| Nippon India Pharma Fund | 2.77% | 2.26% | -0.43 pp |
| SBI ELSS Tax Saver Fund | 2.04% | 0.51% | -0.38 pp |
| Nippon India Multi Cap Fund | 1.97% | 0.28% | -0.04 pp |
Scorecard
- Performance
- Low
- Valuation
- High
- Growth
- Avg
- Profitability
- High
- Entry point
- Good
- Red flags
- Avg
Analyst coverage, holdings and scorecard from market data; not a recommendation by Rajat Finance.
Risk & trend
From 292 daily sessions to 18 Nov 2026.
Risk
- Volatility (1Y)
- 29.4%
- Downside volatility
- 29.8%
- Worst 5% of days
- 2.7%
- Average of that tail
- 4.1%
- Max drawdown (1Y)
- 39.2%
- Below its peak
- 37.1%
Against the market
- Beta vs Nifty 50
- 0.51
- Correlation
- 0.23
- Relative strength (3M)
- -12.4%
- ATR (14)
- 3.2%
Return
- Return 1M
- -1.9%
- Return 3M
- -8.5%
- Return 6M
- -35.3%
- Return 1Y
- -21.5%
- vs 200-day average
- -22.0%
Momentum
- RSI (14)
- 43.0
- MACD histogram
- 2.84
- Stochastic %K
- 52.6
- ADX (14)
- 16.4
- +DI / −DI
- 16.8 / 23.1
- Money flow index
- 26.7
Participation
- Delivery (20d avg)
- 53.7%
- vs its 60-day baseline
- -3.4 pts
- Volume vs 20-day
- -0.1σ
- Close vs day's VWAP
- +0.0%
- 52-week position
- 5 / 100
These describe what this stock's price has already done. They are not forecasts, signals or recommendations, and a dash means the figure was withheld for want of enough history rather than being zero.
Financial quality
From consolidated statements to 30 Sept 2026.
No F-Score: it needs two reporting periods a year apart that carry both an income statement and a balance sheet, and this company's filings do not yet line up that way. The ratios below need only the one period and are unaffected.
- Free cash flow
- ₹373 Cr
- FCF yield
- 5.2%
- Cash conversion
- 2.26
- Accruals ratio
- -0.070
- Net debt
- ₹1,404 Cr
- Net debt / equity
- 0.68
- EV / sales
- 1.13
- Capex intensity
- 1.8%
Computed from filed statements, not filed themselves. A dash means an input was absent, and the score counts only the criteria that could actually be tested.
Insider trades
| Person | Type | Shares | Value | Disclosed |
|---|---|---|---|---|
Alka Ajit Rangnekar Directors Immediate Relative · Off Market | Buy | 3,725 | ₹24.5 L | 1 Sept 2026 |
AGILEMED INVESTMENTS PRIVATE LIMITED Promoters · Revokation of Pledge | Pledge released | 41,71,970 | ₹340 Cr | 26 Dec 2025 |
Disclosures filed with NSE under SEBI (Prohibition of Insider Trading) Regulations. Pledges and releases are not trades and are not counted above.
Corporate actions
Company announcements
Daily Buyback Report
Daily Buyback Report
Daily Buyback Report
Communication to Shareholders- BuyBack
Intimation of Schedule of Analyst / Institutional Investor Meeting
Newspaper Publication of Public Announcement - Buyback
Submission of Board Resolution and Public Announcement - Buyback.
Outcome of Board Meeting held on November 06, 2026, approving the buyback of equity shares.
The Exchange has received the Disclosures of reasons for encumbrance by promoter of listed companies under Reg. 31(1) read with Regulation 28(3) of SEBI (SAST) Regulations, 2011 on October ....
The Exchange has received the Disclosures of reasons for encumbrance by promoter of listed companies under Reg. 31(1) read with Regulation 28(3) of SEBI (SAST) Regulations, 2011 on October ....
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on October 30, 2026 for Agilemed Investments Pvt Ltd
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on October 30, 2026 for Lone Furrow Investments Pvt Ltd
Trading Window Closure Under SEBI (Prohibition of Insider Trading) Regulations, 2015
Medplus Health Services Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/11/2026 ,inter alia, to consider and approve Buy-Back of Equity Shares.
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for ICICI Prudential Mutual Fund
Filed with BSE (scrip 543427); the last 45 days. Documents open at bseindia.com.
Documents
Annual reports
Earnings calls
- Oct 2026SlidesRecording
- Jul 2026TranscriptSlidesRecording
- Jul 2026Slides
- May 2026TranscriptSlidesRecording
- Feb 2026TranscriptSlidesRecording
- Nov 2025TranscriptSlides
Documents open at BSE or the rating agency that issued them.
Sourced from the company's NSE XBRL filing dated 28 Oct 2026 (unaudited). View the source filing. Figures are as filed and are not investment advice.
Medplus Health Services: common questions
Answered from the figures on this page.